Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Spruce Biosciences (SPRB)
NASDAQ:SPRB
Holding SPRB?
Track your performance easily
SPRB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.41 - $5.95
Previous Close$0.55
Volume229.14K
Average Volume (3M)401.47K
Market Cap
$22.58M
Enterprise Value-$35.33M
Total Cash (Recent Filing)$60.05M
Total Debt (Recent Filing)$2.15M
Price to Earnings (P/E)―
Beta1.99
Next Earnings
Mar 12, 2025EPS Estimate
-$0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding41,302,599
10 Day Avg. Volume281,748
30 Day Avg. Volume401,472
Standard Deviation0.39
R-Squared0.09
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.39
Price to Sales (P/S)2.83
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-4.99
Enterprise Value/Gross Profit-3.50
Enterprise Value/Ebitda0.91
Forecast
1Y Price Target
$2.33Price Target Upside326.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Spruce Biosciences News
PremiumCompany Announcements
Spruce Biosciences Reports Q3 2024 Earnings and UpdatesBulls Say, Bears Say
Bulls Say
Clinical TrialsTildacerfont is an oral, non-steroid, highly selective corticotropin-releasing factor 1 (CRF1) receptor antagonist in development for congenital adrenal hyperplasia (CAH).
Competitive AdvantageRemoving BBIO from the CAH race is an incremental positive for SPRB, which could be poised to have the second novel CAH drug to market.
Market OpportunityThe CAH opportunity has a large enough rare disease market with ~20K-30K patients in the U.S. and ~250 new patients identified via newborn screening annually.
Bears Say
Clinical Trial OutcomesSPRB did not meet the primary endpoint in the CAHmelia-203 study.
Clinical Trial ResultsSPRB reported disappointing Phase 2b CAHmelia-203 data with no dose response or reduction in A4 from baseline.
Drug EfficacyTildacerfont showed no effect on A4 in CAHmelia-203, likely due to low drug exposure and a hard-to-treat population.
---
Ownership Overview
18.30% Insiders
2.60% Mutual Funds
24.66% Other Institutional Investors
52.43% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SPRB FAQ
What was Spruce Biosciences’s price range in the past 12 months?
Spruce Biosciences lowest stock price was $0.41 and its highest was $5.95 in the past 12 months.
What is Spruce Biosciences’s market cap?
Currently, no data Available
When is Spruce Biosciences’s upcoming earnings report date?
Spruce Biosciences’s upcoming earnings report date is Mar 12, 2025 which is in 80 days.
How were Spruce Biosciences’s earnings last quarter?
Spruce Biosciences released its earnings results on Nov 11, 2024. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.238 by $0.028.
Is Spruce Biosciences overvalued?
According to Wall Street analysts Spruce Biosciences’s price is currently Undervalued.
Does Spruce Biosciences pay dividends?
Spruce Biosciences does not currently pay dividends.
What is Spruce Biosciences’s EPS estimate?
Spruce Biosciences’s EPS estimate is -$0.22.
How many shares outstanding does Spruce Biosciences have?
Spruce Biosciences has 41,302,600 shares outstanding.
What happened to Spruce Biosciences’s price movement after its last earnings report?
Spruce Biosciences reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.238. Following the earnings report the stock price went down -1.852%.
Which hedge fund is a major shareholder of Spruce Biosciences?
Among the largest hedge funds holding Spruce Biosciences’s share is Aisling Capital Management LP. It holds Spruce Biosciences’s shares valued at N/A.
---
Spruce Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.33 (326.27% Upside)
$2.33 (326.27% Upside)
Blogger Sentiment
Bullish
SPRB Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 7.2%
Last 30 Days ▼ 7.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.14%
12-Months-Change
Fundamentals
Return on Equity
-57.55%
Trailing 12-Months
Asset Growth
-42.38%
Trailing 12-Months
Company Description
Spruce Biosciences
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
---
SPRB Earnings Call
Q4 2024
0:00 / 0:00
---
SPRB Stock 12 Month Forecast
Average Price Target
$2.33
▲(326.27% Upside)
Technical Analysis
Best Analysts Covering SPRB
1 Year
1 Year Success Rate
4/16 ratings generated profit
1 Year Average Return
-28.78%
reiterated a buy rating 3 months ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -28.78% per trade.
---